KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationInvestment in Debt & EquityLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Inovio Pharmaceuticals (INO) Investment in Debt & Equity (2020 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Investment in Debt & Equity for 6 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Investment in Debt & Equity rose 30.35% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2025, up 30.35% year-over-year, with the annual reading at $2.1 million for FY2025, 30.35% up from the prior year.
  • Investment in Debt & Equity hit $2.1 million in Q4 2025 for Inovio Pharmaceuticals, down from $2.5 million in the prior quarter.
  • In the past five years, Investment in Debt & Equity ranged from a high of $3.9 million in Q2 2021 to a low of $1.6 million in Q4 2024.
  • Historically, Investment in Debt & Equity has averaged $2.7 million across 5 years, with a median of $2.6 million in 2024.
  • Biggest five-year swings in Investment in Debt & Equity: crashed 48.62% in 2022 and later skyrocketed 40.61% in 2023.
  • Year by year, Investment in Debt & Equity stood at $3.9 million in 2021, then plummeted by 48.62% to $2.0 million in 2022, then soared by 38.52% to $2.8 million in 2023, then plummeted by 41.95% to $1.6 million in 2024, then soared by 30.35% to $2.1 million in 2025.
  • Business Quant data shows Investment in Debt & Equity for INO at $2.1 million in Q4 2025, $2.5 million in Q3 2025, and $3.1 million in Q2 2025.